All relevant data are within the paper and its Supporting Information files.

Background {#sec005}
==========

Hip fractures, or fractures of the femoral neck, are a major public health problem and are the leading cause of morbidity and mortality in people aged ≥65 years in many countries. Hip fracture is also one of the most common causes of admission to nursing homes. An estimated 1.7 million hip fractures occurred worldwide in the year 1990 \[[@pone.0126488.ref001]\]. The number of people sustaining a hip fracture continues to rise because of an increasing elderly population. Hip fractures also pose a substantial challenge to both patients and healthcare systems worldwide. Currently, over 320,000 hip fractures occur in North America alone each year, and this number is expected to rise to 580,000 by 2040 with healthcare costs exceeding 10 billion dollars \[[@pone.0126488.ref002], [@pone.0126488.ref003]\]. Thus, factors related to hip fracture development need better understanding.

Considering our widespread exposure to fluoride in drinking water, the effect of fluoride on hip fracture risk is an important public health issue. Fluoride in drinking water derives from natural sources or is added to protect dental health. People are exposed daily to fluoride through food and water. In the past 60 years, the possible adverse effects of fluoride on human health have been controversial. The cariostatic benefit from water fluoridation is indisputable. However, results from epidemiologic studies have been contradictory. Some studies have suggested a positive association between the concentration of fluoride in water and incidence of fractures \[[@pone.0126488.ref004]--[@pone.0126488.ref007]\], but others have found no association \[[@pone.0126488.ref008]--[@pone.0126488.ref015]\] or even an inverse relation \[[@pone.0126488.ref016], [@pone.0126488.ref017]\]. Therefore, the association between fluoride exposure in drinking water and hip fracture risk remains unclear. Therefore, a quantitative and systematic summary of the evidence should be performed using meta-analysis. In the present study, we conducted a meta-analysis to confirm the hypothesis whether fluoride exposure in drinking water has increased or decreased the risk of hip fracture.

Methods {#sec006}
=======

Search strategy {#sec007}
---------------

We searched the PubMed and EMBASE databases (from time of inception until March 2014) to identify relevant studies that investigated the association between fluoride exposure in drinking water and hip fracture risk. The following search terms were used: "fluorides" or "fluoride" or "fluoridated" or "fluoridation" and "hip fracture"or "hip fractures" filtered by Human without language restrictions. We also reviewed the reference lists of pertinent articles and recent reviews.

Inclusion and exclusion criteria {#sec008}
--------------------------------

Studies were considered acceptable for inclusion in the meta-analysis if they met the following criteria: (1) evaluating the association between fluoride exposure in drinking water and hip fracture risk with obtainable full text; (2) providing adjusted and/or unadjusted hazard ratios (HRs), odds ratios (ORs), and relative risks (RRs) with corresponding 95% confidence interval (CI) or raw data for calculating crude HRs, ORs, or RRs. Studies were excluded if they met the following criteria: letters, comments, correspondences, conference reports, or laboratory studies; or they did not contain enough data for risk estimates calculation. If duplicated data were present in several studies, only the most recent, largest, or most comprehensive study was included. Two authors (JKS and XHY) independently evaluated the eligibility of all retrieved studies, and disagreements were resolved by discussion or consultation with a third author (GLH).

Data extraction {#sec009}
---------------

Two authors (JKS and XHY) independently extracted data of the characteristics of the selected studies using a standardized data extraction form. Data were recorded as follows: first author's surname, publication year, study design, country, number of subjects (cases/controls), gender, follow-up duration, period of fluoride exposure, crude and/or adjusted point estimates and corresponding 95% CIs for each category, and covariate features included in the multivariable model. Disagreements were resolved by discussion and consensus with a third author (GLH).

Quality assessment {#sec010}
------------------

The methodological quality of each trial was evaluated using Newcastle---Ottawa Scale (NOS). Three major components were collected: selection of study groups (0 to 4 points), ascertainment for exposure of interest in the studies (0 to 3 points), and quality of adjustment for confounding factors (0 to 2 points). A higher score represented better methodological quality. The quality of each study was graded either low (0 to 4) or high (5 to 9) level.

Statistical analysis {#sec011}
--------------------

RRs with corresponding 95% CIs were used as common measures of association between fluoride exposure in drinking water and hip fracture risk. Given the low absolute risk of hip fracture, ORs and HRs were directly considered approximations of RRs. Six studies \[[@pone.0126488.ref007], [@pone.0126488.ref011], [@pone.0126488.ref013]--[@pone.0126488.ref015], [@pone.0126488.ref017]\] did not report overall risk estimates but separately presented results for men and women. Therefore, we combined the results using random effects and included the pooled risks estimates in the primary analysis. One study \[[@pone.0126488.ref016]\] reported stratified risks estimates by age and gender, and we combined these estimates using a random-effects model and then used the pooled estimates for the meta-analysis. For three studies \[[@pone.0126488.ref005], [@pone.0126488.ref010], [@pone.0126488.ref012]\] that reported stratified risks estimates by fluoride exposure levels, we only used the estimates for the highest versus the lowest category of fluoride exposure levels. One study \[[@pone.0126488.ref009]\] presented separate risks estimates for durations of exposure, and we only used the estimates for the highest versus the lowest category of fluoride exposure duration.

Statistical heterogeneity was evaluated using Cochrane Q test (significance level at \<0.10). The degree of heterogeneity was quantified using I^2^ statistic, which represents the percentage of the total variability across studies \[[@pone.0126488.ref018]\]. Studies with an I^2^ statistic of 25% to 50% have low heterogeneity, those with 50% to 75% have moderate heterogeneity, and those with \>75% have high heterogeneity. An I^2^ value \> 50% indicates significant heterogeneity. Fixed-effects model was used as pooling method for moderate or low heterogeneity (I^2^ \< 50%), whereas random-effects model (REM) was used for significant heterogeneity (I^2^ \> 50%). Given that patient characteristics, study design, and other confounding factors were inconsistent among studies, we further conducted sensitivity analyses to explore possible explanations for heterogeneity and to examine the influence of various exclusion criteria on the overall pooled estimate. We also investigated the influence of individual studies on the overall risk estimate. We performed meta-regression to explore the sources of heterogeneity in the association between exposure to fluoride in drinking water and hip fracture risk as reported in individual studies, particularly the effects of five study-level characteristics (country, gender, quality of Newcastle---Ottawa Scale scores, adjustment for covariates and sample size). The presence of publication bias was assessed using Begg's and Egger's tests \[[@pone.0126488.ref019], [@pone.0126488.ref020]\]. A P value \< 0.05 was considered statistically significant, unless otherwise specified. All statistical analyses were performed using STATA version 12.0 (Stata Corporation, College Station, Texas, USA).

Results {#sec012}
=======

Study selection {#sec013}
---------------

Upon search strategy, 408 records were initially retrieved. The majority of the retrieved articles were excluded after reviewing titles and abstracts, mainly because they were reviews, letters, comments, or irrelevant to our analysis. Twenty-four articles were considered of interest, and full text of each was retrieved for detailed evaluation. Ten out of these 24 articles were excluded. Finally, 14 articles were included in the meta-analysis ([Fig 1](#pone.0126488.g001){ref-type="fig"}).

![Flow chart of identification of eligible studies to final inclusion.](pone.0126488.g001){#pone.0126488.g001}

Study characteristics {#sec014}
---------------------

The characteristics of all included articles are presented in Tables [1](#pone.0126488.t001){ref-type="table"} and [2](#pone.0126488.t002){ref-type="table"}. Fourteen observational articles involving more than 73,411,368 individuals and 319,608 patients were identified. Among these articles, thirteen were cohort studies \[[@pone.0126488.ref004], [@pone.0126488.ref005], [@pone.0126488.ref007]--[@pone.0126488.ref017]\], and one was a case-control study \[[@pone.0126488.ref006]\]. Seven articles were based in the United States \[[@pone.0126488.ref004], [@pone.0126488.ref007]--[@pone.0126488.ref009], [@pone.0126488.ref011], [@pone.0126488.ref014], [@pone.0126488.ref015]\], five in Europe \[[@pone.0126488.ref005], [@pone.0126488.ref006], [@pone.0126488.ref010], [@pone.0126488.ref016], [@pone.0126488.ref017]\], and two in Asia \[[@pone.0126488.ref012], [@pone.0126488.ref013]\]. The articles were published from 1983 to 2013. The sample size of the observational studies ranged from 506 to 70,000,000, with the eight largest studies recruited over 100,000 participants.

10.1371/journal.pone.0126488.t001

###### Characteristic of studies included in the meta-analysis.

![](pone.0126488.t001){#pone.0126488.t001g}

  Study         Year   Country          Study design                           No. of subjects   No. of patients   Sex       Age,Median(Range),yrs   Flouride exposure (yrs)   Follow-up(yrs)   Adjustment for covariates
  ------------- ------ ---------------- -------------------------------------- ----------------- ----------------- --------- ----------------------- ------------------------- ---------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Simonen O     1985   Finland          Cohort study                           133,398           395               F and M   NA(≥50)                 19                        11               Unadjust
  Sowers MF     1991   United States    A prospective cohort study             506               7                 F         NA(20--80)              NA                        5                Adjusted for age and body size
  Danielson C   1992   United States    Ecological cohort                      6,049             246               F and M   NA(≥65)                 20                        7                Unadjust
  Jacobsen SJ   1992   United States    Cohort study                           70,000,000        218,951           F and M   NA(≥65)                 NA                        4                Adjusted for age
  Jacobsen SJ   1993   United States    A retrospective-prospective cohort     NA                751               F and M   NA(≥50)                 20                        10               Adjusted for age.
  Cauley JA     1995   United States    A prospective cohort study             2,076             41                F         NA(≥65)                 12.7 ± 8.0                6.1              Adjusted for age, BMI, total calcium intake (diet plus supplements), history of osteoporosis, surgical menopause. history of kills in past year, drinks per week, education, current estrogen use. current thiazidc diuretic use, ever used bottled water.
  Karagas MR    1996   United States    A retrospective cohort study           444,000           28,194            F and M   NA(65--89)              NA                        4                Unadjust
  Lehmann R     1998   Germany          A retrospective cohort                 623,602           1,198             F and M   NA(≥35)                 7--17                     2                Unadjust
  Kurttio P     1999   Finland          A retrospective cohort study           144,627           4,449             F and M   NA(50--80)              NA                        13               Adjusted for age and area
  Phipps KR     2000   United States    Multicentre prospective cohort study   7,129             231               F         74.2(≥65)               44                        7                Adjusted for age, weight, education, muscle strength, surgical menopause, calcium intake, drinks/week, current oestrogen use, current thiazide use, noninsulin dependent diabetes, current thyroid hormone use, walking for exercise, and smoking status
  Hillier S     2000   United Kingdom   Case-control study                     1,041             514               F and M   NA(≥50)                 NA                        NA               Adjusted for age and gender、all potential confounders
  Li Y          2001   china            Cohort study                           8266              56                F and M   62.8(NA)                \>25                      NA               Unadjust
  Park EY       2008   Korean           Cohort study                           1,567,397         3,842             F and M   NA(≥65)                 NA                        7                Unadjust
  Näsman P      2013   Sweden           Cohort study                           473,277           60,733            F and M   62.8(44.0--87.0)        NA                        16.8             Adjusted for gender, age group, county of residence, calendar group

F, female; M, male; NA, not available.

10.1371/journal.pone.0126488.t002

###### The effect size across included studies.
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  Study         Year   exposure to waterfluoridation    RRs/HRs/ORs (95%CIs)
  ------------- ------ -------------------------------- ----------------------
  Simonen O     1985   1.0 vs. 0--0.1mg/l               
                       female                           1.5(1.2 to 1.8)
                       male                             2.5(1.6 to 3.9)
  Sowers MF     1991   4.0±0.1 vs. 1.0 mg/l             2.2(1.1 to 4.7)
  Danielson C   1992   1.0 vs. 0.3ppm                   
                       female                           1.27(1.08 to 1.46)
                       male                             1.41(1.0 to 1.81)
  Jacobsen SJ   1992   nonfluoradated vs. fluoridated   
                       female                           1.17(1.13 to 1.22)
                       male                             1.08(1.06 to 1.1)
  Jacobsen SJ   1993   nonfluoradated vs. fluoridated   
                       male                             0.78(0.37 to 1.66)
                       female                           0.6(0.42 to 0.85)
  Cauley JA     1995   1.01±0.21 vs. 0.15±0.10 mg/l     
                       0 year                           1.0
                       1--10 years                      0.89(0.42 to 1.92)
                       11--20years                      0.58(0.14 to 2.48)
                       \>20 years                       0.44(0.1 to 1.86)
  Karagas MR    1996   nonfluoradated vs. fluoridated   
                       male                             1(0.92 to 1.09)
                       female                           1.01(0.96 to 1.06)
  Lehmann R     1998   0.77--1.20 vs. 0.08--0.36mg/l    
                       male                             
                       60--64 years                     2.14(0.89 to 5.2)
                       65--69 years                     0.55(0.22 to 1.39)
                       70--74 years                     0.78(0.27 to 1.39)
                       75--79 years                     1.05(0.65 to 1.69)
                       80--84 years                     1.02(0.67 to 1.55)
                       ≥80 years                        1.92(1.07 to 3.45)
                       female                           
                       60--64 years                     0.9(0.51 to 1.58)
                       65--69 years                     1.56(1 to 2.44)
                       70--74 years                     1.09(0.76 to 1.57)
                       75--79 years                     1.38(1.06 to 1.8)
                       80--84 years                     1.2(0.95 to 1.52)
                       ≥80 years                        1.41(1.1 to 1.81)
  Kurttio P     1999   female                           
                       ≤0.10 mg/l                       1.0
                       0.11--0.30 mg/l                  0.93(0.84 to 1.02)
                       0.31--0.50 mg/l                  1.12(0.93 to 1.34)
                       0.51--1.00 mg/l                  1.12(0.96 to 1.31)
                       1.10--1.50 mg/l                  1.08(0.88 to 1.32)
                       \>1.50 mg/l                      1.08(0.8 to 1.46)
                       male                             
                       ≤0.10 mg/l                       1.0
                       0.11--0.30 mg/l                  1.05(0.9 to 1.22)
                       0.31--0.50 mg/l                  0.72(0.51 to 1.02)
                       0.51--1.00 mg/l                  1.03(0.81 to 1.32)
                       1.10--1.50 mg/l                  0.67(0.46 to 0.97)
                       \>1.50 mg/l                      0.98(0.61 to 1.6)
  Phipps KR     2000   mixed exposure                   0.73(0.49 to 1.09)
                       continuous exposure              0.69(0.5 to 0.96)
  Hillier S     2000   ≥0.9 vs. \<0.9mg/l               1(0.7 to 1.5)
  Li Y          2001   0.25--0.34 mg/l                  0.99(0.21 to 4.77)
                       0.58--0.73 mg/l                  1.12(0.35 to 3.62)
                       1.00--1.06 mg/l                  1.0
                       1.45--2.19 mg/l                  2.13(0.76 to 5.96)
                       2.62--3.56 mg/l                  1.73(0.56 to 5.33)
                       4.32--7.97 mg/l                  3.26(1.20 to 8.82)
  Park EY       2008   fluoridated vs. nonfluoradated   
                       female                           0.88(0.77 to 1)
                       male                             0.91(0.84 to 0.99)
  Näsman P      2013   Very low \<0.3                   1.0
                       Low 0.3--0.69                    0.97(0.94 to 0.99)
                       Mendium 0.7--1.49                0.97(0.94 to 1)
                       High ≥1.5                        0.98(0.93 to 1.04)

All 14 studies reported exposure to fluoride in drinking water. Ten studies were designed to evaluate the RRs of hip fracture \[[@pone.0126488.ref004], [@pone.0126488.ref005], [@pone.0126488.ref007]--[@pone.0126488.ref009], [@pone.0126488.ref011], [@pone.0126488.ref013]--[@pone.0126488.ref015], [@pone.0126488.ref017]\], three were designed to evaluate the ORs of hip fracture \[[@pone.0126488.ref006], [@pone.0126488.ref012], [@pone.0126488.ref016]\], and one was designed to evaluate the HRs of hip fracture \[[@pone.0126488.ref010]\]. Three studies investigated only women \[[@pone.0126488.ref004], [@pone.0126488.ref008], [@pone.0126488.ref009]\], whereas eleven studies investigated both women and men \[[@pone.0126488.ref005]--[@pone.0126488.ref007], [@pone.0126488.ref010]--[@pone.0126488.ref017]\]. The average follow-up ranged from 2 years to 16.8 years. Patients were followed up over five years in majority of the studies (64.3%). The association between exposure to water fluoridation and hip fracture risk was the primary outcome of interest for eight studies \[[@pone.0126488.ref005]--[@pone.0126488.ref007], [@pone.0126488.ref010], [@pone.0126488.ref013]--[@pone.0126488.ref015], [@pone.0126488.ref017]\], whereas this association was a secondary subject in six studies \[[@pone.0126488.ref004], [@pone.0126488.ref008], [@pone.0126488.ref009], [@pone.0126488.ref011], [@pone.0126488.ref012], [@pone.0126488.ref016]\]. Six studies did not adjust for confounding factors \[[@pone.0126488.ref007], [@pone.0126488.ref011]--[@pone.0126488.ref013], [@pone.0126488.ref016], [@pone.0126488.ref017]\], whereas the others controlled a group of conventional risk factors for hip fracture, such as age, gender, area, and smoking \[[@pone.0126488.ref004]--[@pone.0126488.ref006], [@pone.0126488.ref008]--[@pone.0126488.ref010], [@pone.0126488.ref014], [@pone.0126488.ref015]\].

The quality of the included studies was assessed by NOS ([Table 3](#pone.0126488.t003){ref-type="table"}). The median NOS score was 6.5 (range: 4 to 9).

10.1371/journal.pone.0126488.t003

###### Quality assessment of included studies based on Newcastle-Ottawa scale.
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  Author        year   Selection   Comparability   Exposure
  ------------- ------ ----------- --------------- ----------
  Simonen O     1985   3           0               2
  Sowers MF     1991   3           1               2
  Danielson C   1992   3           1               3
  Jacobsen SJ   1992   2           1               2
  Jacobsen SJ   1993   3           1               1
  Cauley JA     1995   3           2               2
  Karagas MR    1996   3           0               2
  Lehmann R     1998   3           0               1
  Kurttio P     1999   4           1               3
  Phipps KR     2000   3           2               2
  Hillier S     2000   3           2               2
  Li Y          2001   3           2               1
  Park EY       2008   3           2               2
  Näsman P      2013   4           2               3

Exposure to fluoride in drinking water and hip fracture risk {#sec015}
------------------------------------------------------------

The overall RR estimates for each study were pooled to determine the total estimates of risk using random-effects model (RRs = 1.05; 95% CIs = 0.96 to 1.15, P = 0.291), and the heterogeneity was significant (P \< 0.001, I^2^ = 82.8%). The results suggested that, exposure to fluoride in drinking water does not increase the incidence of hip fracture risk and substantial heterogeneity was observed ([Fig 2](#pone.0126488.g002){ref-type="fig"}).

![Forest plot of exposure to fluoride in the drinking water and hip fracture risk.\
Studies are pooled with a random-effects model.](pone.0126488.g002){#pone.0126488.g002}

We also conducted meta-analyses based on women aged ≥65 years to explore the effect of exposure to fluoride from drinking water on hip fracture risk, and the results were relatively consistent. No association was observed in exposure to fluoride from drinking water on hip fracture risk (RRs = 1.04, 95% CIs = 0.97 to 1.12, P = 0.30) with substantial evidence of heterogeneity (P \< 0.001, I^2^ = 86.3%) ([Fig 3](#pone.0126488.g003){ref-type="fig"}).

![Forest plot of exposure to fluoride in the drinking water and hip fracture risk among women beyond 65 years.\
Studies are pooled with a random-effects model.](pone.0126488.g003){#pone.0126488.g003}

Sensitivity analyses {#sec016}
--------------------

To explore potential heterogeneity, we performed sensitivity analyses to examine the effects of various exclusion criteria on combined risk estimates. Sensitivity analyses based on adjustment for covariates, effect measure, country, sex, sample size (Large, cases ≥ 100; Small, cases \<100), quality of Newcastle---Ottawa Scale scores (High, NOS score ≥5, Low, NOS score, \<5), and follow-up period yielded similar results with substantial evidence of heterogeneity ([Table 4](#pone.0126488.t004){ref-type="table"}, [Fig 4](#pone.0126488.g004){ref-type="fig"}). Further exclusion of any single study did not significantly alter the combined RRs, which ranged from 1.02 (95% CI = 0.94 to 1.12) to 1.08 (95% CI = 0.99 to 1.17).

10.1371/journal.pone.0126488.t004

###### Sensitive analyses based on various exclusion criteria.
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                              Studies,N   RRs,95%CIs         P value   P value for heterogeneity   I^2^(%)
  --------------------------- ----------- ------------------ --------- --------------------------- ---------
  total                       14          1.05(0.96--1.15)   0.291     0.000                       82.8
  Country                                                                                          
  United States               7           1.01(0.87--1.17)   0.898     0.000                       84.1
  Europe                      5           1.13(0.95--1.35)   0.168     0.001                       79.7
  Asia                        2           1.55(0.45--5.39)   0.491     0.012                       84.3
  Gender                                                                                           
  Female                      11          1.07(0.98--1.17)   0.143     0.000                       83.5
  Male                        8           1.13(0.98--1.30)   0.167     0.000                       86.5
  Effect measure                                                                                   
  RRs                         10          1.02(0.91--1.15)   0.712     0.000                       83.9
  ORs                         3           1.28(0.91--1.81)   0.162     0.087                       59.0
  HRs                         1           0.98(0.93--1.04)   0.479     NA                          NA
  Sample size                                                                                      
  Large(cases ≥ 100)          11          1.03(0.95--1.13)   0.451     0.000                       84.5
  Small(cases \<100)          3           1.72(0.67--4.41)   0.263     0.078                       60.9
  Adjustment for covariates                                                                        
  Yes                         8           0.96(0.83--1.10)   0.529     0.000                       75.0
  No                          6           1.16(1.00--1.34)   0.050     0.000                       89.4
  NOS score                                                                                        
  High(≥5)                    13          1.02(0.94--1.12)   0.600     0.000                       80.8
  Low(\<5)                    1           1.26(1.12--1.42)   0.000     NA                          NA
  Follow-up duration(years)                                                                        
  ≥5                          8           0.99(0.86--1.15)   0.978     0.000                       83.0
  \<5                         3           1.11(0.99--1.25)   0.075     0.000                       87.1
  NA                          2           1.64(0.52--5.16)   0.394     0.030                       78.8

HRs, hazard ratios, ORs, odds ratios, RRs, relative risks, CIs, confidence intervals; NA, not available.

![Sensitivity analyses based on various exclusion criteria.](pone.0126488.g004){#pone.0126488.g004}

Meta-regression {#sec017}
---------------

Considering the relatively high heterogeneity exhibited in the trials, a meta-regression was conducted to explore the predefined possible sources of heterogeneity. None of the regression coefficients were statistically significant ([Table 5](#pone.0126488.t005){ref-type="table"}), suggesting that country, gender, quality of Newcastle---Ottawa Scale scores, adjustment for covariates and sample size were insignificant sources of heterogeneity.

10.1371/journal.pone.0126488.t005

###### Effects of study variables by meta-regression.
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  Covariant                         Coefficient   P value   95% CIs
  --------------------------------- ------------- --------- -----------------
  Country(Ref = Europe)                                     
  Asia                              −0.004        0.991     −0.740 to 0.732
  United States                     −0.161        0.475     −0.640 to 0.318
  Adujusted for covariates          −0.243        0.180     −0.615 to 0.129
  Sample size                       −0.633        0.115     −1.445 to 0.179
  Newcastle---Ottawa Scale scores   −0.051        0.451     −0.193 to 0.091
  year of publication               -0.014        0.276     −0.039 to 0.012

Publication bias {#sec018}
----------------

Both Begg's (rank correlation test) and Egger's funnel plot asymmetry test (regression method) in the meta-analysis indicated no significant publication bias (Begg's test, P = 0.74; Egger's test, P = 0.47; [Fig 5](#pone.0126488.g005){ref-type="fig"}).

![Funnel plots of exposure to fluoride in the drinking water and hip fracture risk for assessment of publication bias.](pone.0126488.g005){#pone.0126488.g005}

Discussion {#sec019}
==========

To our knowledge, this meta-analysis is the first to explore the effect of fluoride exposure on hip fracture patients. The pooled results from the meta-analysis of 14 observational studies using random-effects model provided evidence that chronic fluoride exposure from drinking water does not significantly increase the incidence of hip fracture. The combined estimates were robust across sensitivity and meta-regression. Few evidence of publication bias was also observed.

Several plausible mechanisms may explain the lack of association between fluoride exposure from drinking water and hip fracture risk in the present analysis. Fluoride is a bone seeker and has strong effects on bone cell function, bone structure, and bone strength \[[@pone.0126488.ref021]\]. Fluoride can affect bone in at least two ways. Fluoride ions can replace hydroxyl ions in the hydroxyapatite lattice, thereby increasing fluoride concentrations in plasma and osteoblastic differentiation and activity. Such changes play a crucial effect on fracture risk. This effect has only been observed when intake has been substantially higher than expected from water fluoridation. However, the implications of lower exposure for fracture risk are uncertain.

The effects of fluoride on bone have also been investigated in a randomized controlled trial of high-dose sodium fluoride (75 mg daily) as a treatment for osteoporosis. During a four-year period, the intervention led to a substantial increase in bone density in the spine \[[@pone.0126488.ref022]\]. Although this study indicated a hazard from high doses of fluoride in people with established osteoporosis, the risk cannot be necessarily extrapolated to much lower doses received by the general population from fluoride in water supplies.

Danielson et al. \[[@pone.0126488.ref007]\], Kurttio et al. \[[@pone.0126488.ref005]\], and Sowers et al. \[[@pone.0126488.ref004]\] reported that exposure to fluoride could increase hip fracture risk among older women, whereas Cauley et al. \[[@pone.0126488.ref009]\] and Phipps et al. \[[@pone.0126488.ref008]\] indicated that fluoride exposure slightly decreases hip fracture risk among older women. Jacobsen et al. \[[@pone.0126488.ref014]\], Karagas et al. \[[@pone.0126488.ref011]\], Näsman P et al. \[[@pone.0126488.ref010]\], and Park et al. \[[@pone.0126488.ref013]\] have found no association. In the present meta-analyses, no statistically significant association between fluoride exposure from drinking water and hip fracture risk was observed among older women. In older ages, several reasons account for fluoride effects. One explanation could be the effect of calcium. Calcium supplementation is usually recommended for elderly patients. However, excess dietary calcium intake may prohibit fluoride absorption, which reduces probability of fluoride effect \[[@pone.0126488.ref023]\]. Calcium absorption is also different in elderly patients, which decreases with age as a result of various possible mechanisms, including decreased vitamin D intake, synthesis, and metabolism \[[@pone.0126488.ref024]\]. Elderly persons also tend to reduce their food intake, which further decreases their opportunity for adequate nutrition. The kinetics of fluoride may be different in older ages \[[@pone.0126488.ref025]\]. The rate of bone formation decreases as the skeleton ages, and less fluoride is taken up by older bone \[[@pone.0126488.ref021]\], thereby reducing potential effects of fluoride.

The present meta-analysis has some limitations. First, our meta-analysis was based on observational studies, and half of the included studies controlled some confounding factors, such as age and gender. However, other confounding factors (estrogen level, total calcium intake, diet, and level of fluoride exposure) are difficult to control in epidemiological studies. Second, although few evidence of publication bias was observed, the statistical power for these tests was limited because of the relatively small number of included studies. Third, significant heterogeneity was detected in our meta-analysis. Heterogeneity between studies should not be ignored even if it is highly common in the meta-analysis. We also performed sensitivity analyses and meta-regression to determine the sources of heterogeneity, but heterogeneity was still observed. Fourth, because the majority of studies using different methods used to assess and categorize fluoride exposure among studies ([Table 1](#pone.0126488.t001){ref-type="table"}), our findings are likely to be influenced by the misclassification of exposure. In cohort studies, this misclassification would likely be non-differential if the exposure variable was dichotomous, and thereby result in an underestimate of the true association, whereas the influence of a misclassification on the results in case-control studies is less predictable. Moreover, the potential for misclassification of exposure to fluoride may contribute to the heterogeneity for all studies in the summary analysis. Therefore, this result should be considered with caution because of exposure misclassification. Overall, these aforementioned limitations may affect our final conclusions.

In conclusion, limited evidence suggests that chronic fluoride exposure from drinking water does not significantly increase the risk of hip fracture. Although these findings are encouraging, the results of this meta-analysis should be explained with caution because of potential confounding factors, heterogeneity, and exposure misclassification. Further large-scale and well-designed trials on this topic are needed.
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